Global Hemophilia Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.

According to APO Research, The global Hemophilia Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hemophilia Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Hemophilia Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Hemophilia Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Hemophilia Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Hemophilia Gene Therapy include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure and Freeline Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hemophilia Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Hemophilia Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemophilia Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Hemophilia Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Hemophilia Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Hemophilia Gene Therapy Segment by Company

Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics

Hemophilia Gene Therapy Segment by Type

Hemophilia A
Hemophilia B

Hemophilia Gene Therapy Segment by Application

Hemophilia A Gene Therapy
Hemophilia B Gene Therapy

Hemophilia Gene Therapy Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Hemophilia Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemophilia Gene Therapy industry.
Chapter 3: Detailed analysis of Hemophilia Gene Therapy companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Gene Therapyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Market Analysis by Type
1.2.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Hemophilia A
1.2.3 Hemophilia B
1.3 Market Analysis by Application
1.3.1 Global Hemophilia Gene Therapy Market Size Growth Rate by Application: 2020 VS 2024 VS 2031
1.3.2 Hemophilia A Gene Therapy
1.3.3 Hemophilia B Gene Therapy
1.4 Global Market Growth Prospects
1.5 Global Hemophilia Gene Therapy Growth Trends by Region
1.5.1 Global Hemophilia Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
1.5.2 Hemophilia Gene Therapy Market Size by Region (2020-2025)
1.5.3 Hemophilia Gene Therapy Market Size by Region (2026-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
1.8 Years Considered
2 Global Hemophilia Gene Therapy Market Dynamics
2.1 Hemophilia Gene Therapy Industry Trends
2.2 Hemophilia Gene Therapy Industry Drivers
2.3 Hemophilia Gene Therapy Industry Opportunities and Challenges
2.4 Hemophilia Gene Therapy Industry Restraints
3 Competitive Landscape by Company
3.1 Global Hemophilia Gene Therapy Revenue by Company (2020-2025)
3.2 Global Hemophilia Gene Therapy Players Revenue Ranking, 2023 VS 2024 VS 2025
3.3 Global Hemophilia Gene Therapy Key Company Head office and Area Served
3.4 Global Hemophilia Gene Therapy Company, Product Type & Application
3.5 Global Hemophilia Gene Therapy Company Establishment Date
3.6 Market Competitive Analysis
3.6.1 Global Hemophilia Gene Therapy Market CR5 and HHI
3.6.2 Global Top 5 and 10 Hemophilia Gene Therapy Players Market Share by Revenue in 2024
3.6.3 2024 Hemophilia Gene Therapy Tier 1, Tier 2, and Tier 3
4 Hemophilia Gene Therapy Market by Type
4.1 Global Hemophilia Gene Therapy Market Size by Type (2020 VS 2024 VS 2031)
4.2 Global Hemophilia Gene Therapy Market Size by Type (2020-2031)
4.3 Global Hemophilia Gene Therapy Market Size Share by Type (2020-2031)
5 Hemophilia Gene Therapy Market by Application
5.1 Global Hemophilia Gene Therapy Market Size by Application (2020 VS 2024 VS 2031)
5.2 Global Hemophilia Gene Therapy Market Size by Application (2020-2031)
5.3 Global Hemophilia Gene Therapy Market Size Share by Application (2020-2031)
6 Company Profiles
6.1 Spark Therapeutics
6.1.1 Spark Therapeutics Comapny Information
6.1.2 Spark Therapeutics Business Overview
6.1.3 Spark Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.1.4 Spark Therapeutics Hemophilia Gene Therapy Product Portfolio
6.1.5 Spark Therapeutics Recent Developments
6.2 Ultragenyx
6.2.1 Ultragenyx Comapny Information
6.2.2 Ultragenyx Business Overview
6.2.3 Ultragenyx Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.2.4 Ultragenyx Hemophilia Gene Therapy Product Portfolio
6.2.5 Ultragenyx Recent Developments
6.3 Shire PLC
6.3.1 Shire PLC Comapny Information
6.3.2 Shire PLC Business Overview
6.3.3 Shire PLC Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.3.4 Shire PLC Hemophilia Gene Therapy Product Portfolio
6.3.5 Shire PLC Recent Developments
6.4 Sangamo Therapeutics
6.4.1 Sangamo Therapeutics Comapny Information
6.4.2 Sangamo Therapeutics Business Overview
6.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Product Portfolio
6.4.5 Sangamo Therapeutics Recent Developments
6.5 Bioverativ
6.5.1 Bioverativ Comapny Information
6.5.2 Bioverativ Business Overview
6.5.3 Bioverativ Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.5.4 Bioverativ Hemophilia Gene Therapy Product Portfolio
6.5.5 Bioverativ Recent Developments
6.6 BioMarin
6.6.1 BioMarin Comapny Information
6.6.2 BioMarin Business Overview
6.6.3 BioMarin Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.6.4 BioMarin Hemophilia Gene Therapy Product Portfolio
6.6.5 BioMarin Recent Developments
6.7 uniQure
6.7.1 uniQure Comapny Information
6.7.2 uniQure Business Overview
6.7.3 uniQure Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.7.4 uniQure Hemophilia Gene Therapy Product Portfolio
6.7.5 uniQure Recent Developments
6.8 Freeline Therapeutics
6.8.1 Freeline Therapeutics Comapny Information
6.8.2 Freeline Therapeutics Business Overview
6.8.3 Freeline Therapeutics Hemophilia Gene Therapy Revenue and Gross Margin (US$ Million) & (2020-2025)
6.8.4 Freeline Therapeutics Hemophilia Gene Therapy Product Portfolio
6.8.5 Freeline Therapeutics Recent Developments
7 North America
7.1 North America Hemophilia Gene Therapy Market Size (2020-2031)
7.2 North America Hemophilia Gene Therapy Market Size by Type
7.2.1 North America Hemophilia Gene Therapy Market Size by Type (2020-2025)
7.2.2 North America Hemophilia Gene Therapy Market Size by Type (2026-2031)
7.2.3 North America Hemophilia Gene Therapy Market Share by Type (2020-2031)
7.3 North America Hemophilia Gene Therapy Market Size by Application
7.3.1 North America Hemophilia Gene Therapy Market Size by Application (2020-2025)
7.3.2 North America Hemophilia Gene Therapy Market Size by Application (2026-2031)
7.3.3 North America Hemophilia Gene Therapy Market Share by Application (2020-2031)
7.4 North America Hemophilia Gene Therapy Market Size by Country
7.4.1 North America Hemophilia Gene Therapy Market Size by Country (2020 VS 2024 VS 2031)
7.4.2 North America Hemophilia Gene Therapy Market Size by Country (2020-2025)
7.4.3 North America Hemophilia Gene Therapy Market Size by Country (2026-2031)
7.4.4 North America Hemophilia Gene Therapy Market Share by Country (2020-2031)
7.4.5 United States
7.4.6 Canada
7.4.7 Mexico
8 Europe
8.1 Europe Hemophilia Gene Therapy Market Size (2020-2031)
8.2 Europe Hemophilia Gene Therapy Market Size by Type
8.2.1 Europe Hemophilia Gene Therapy Market Size by Type (2020-2025)
8.2.2 Europe Hemophilia Gene Therapy Market Size by Type (2026-2031)
8.2.3 Europe Hemophilia Gene Therapy Market Share by Type (2020-2031)
8.3 Europe Hemophilia Gene Therapy Market Size by Application
8.3.1 Europe Hemophilia Gene Therapy Market Size by Application (2020-2025)
8.3.2 Europe Hemophilia Gene Therapy Market Size by Application (2026-2031)
8.3.3 Europe Hemophilia Gene Therapy Market Share by Application (2020-2031)
8.4 Europe Hemophilia Gene Therapy Market Size by Country
8.4.1 Europe Hemophilia Gene Therapy Market Size by Country (2020 VS 2024 VS 2031)
8.4.2 Europe Hemophilia Gene Therapy Market Size by Country (2020-2025)
8.4.3 Europe Hemophilia Gene Therapy Market Size by Country (2026-2031)
8.4.4 Europe Hemophilia Gene Therapy Market Share by Country (2020-2031)
8.4.5 Germany
8.4.6 France
8.4.7 U.K.
8.4.8 Italy
8.4.9 Russia
8.4.10 Nordic Countries
9 China
9.1 China Hemophilia Gene Therapy Market Size (2020-2031)
9.2 China Hemophilia Gene Therapy Market Size by Type
9.2.1 China Hemophilia Gene Therapy Market Size by Type (2020-2025)
9.2.2 China Hemophilia Gene Therapy Market Size by Type (2026-2031)
9.2.3 China Hemophilia Gene Therapy Market Share by Type (2020-2031)
9.3 China Hemophilia Gene Therapy Market Size by Application
9.3.1 China Hemophilia Gene Therapy Market Size by Application (2020-2025)
9.3.2 China Hemophilia Gene Therapy Market Size by Application (2026-2031)
9.3.3 China Hemophilia Gene Therapy Market Share by Application (2020-2031)
10 Asia (Excluding China)
10.1 Asia Hemophilia Gene Therapy Market Size (2020-2031)
10.2 Asia Hemophilia Gene Therapy Market Size by Type
10.2.1 Asia Hemophilia Gene Therapy Market Size by Type (2020-2025)
10.2.2 Asia Hemophilia Gene Therapy Market Size by Type (2026-2031)
10.2.3 Asia Hemophilia Gene Therapy Market Share by Type (2020-2031)
10.3 Asia Hemophilia Gene Therapy Market Size by Application
10.3.1 Asia Hemophilia Gene Therapy Market Size by Application (2020-2025)
10.3.2 Asia Hemophilia Gene Therapy Market Size by Application (2026-2031)
10.3.3 Asia Hemophilia Gene Therapy Market Share by Application (2020-2031)
10.4 Asia Hemophilia Gene Therapy Market Size by Country
10.4.1 Asia Hemophilia Gene Therapy Market Size by Country (2020 VS 2024 VS 2031)
10.4.2 Asia Hemophilia Gene Therapy Market Size by Country (2020-2025)
10.4.3 Asia Hemophilia Gene Therapy Market Size by Country (2026-2031)
10.4.4 Asia Hemophilia Gene Therapy Market Share by Country (2020-2031)
10.4.5 Japan
10.4.6 South Korea
10.4.7 Taiwan
10.4.8 Southeast Asia
10.4.9 India
10.4.10 Australia
11 South America, Middle East & Africa
11.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size (2020-2031)
11.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type
11.2.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2020-2025)
11.2.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Type (2026-2031)
11.2.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Type (2020-2031)
11.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application
11.3.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2020-2025)
11.3.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Application (2026-2031)
11.3.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Application (2020-2031)
11.4 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country
11.4.1 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2020 VS 2024 VS 2031)
11.4.2 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2020-2025)
11.4.3 South America, Middle East & Africa Hemophilia Gene Therapy Market Size by Country (2026-2031)
11.4.4 South America, Middle East & Africa Hemophilia Gene Therapy Market Share by Country (2020-2031)
11.4.5 Brazil
11.4.6 South Africa
11.4.7 Saudi Arabia
11.4.8 Turkey
11.4.9 Argentina
11.4.9 UAE
11.4.9 Egypt
11.4.9 Chile
12 Concluding Insights
13 Appendix
13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources
13.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings